Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shanghai MicroPort Endovascular MedTech (Group) Co EBITDA Margin % Related Terms
Shanghai MicroPort Endovascular MedTech (Group) Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai MicroPort Endovascular MedTech (Group) Co EBITDA Margin % Chart
Shanghai MicroPort Endovascular MedTech (Group) Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai MicroPort Endovascular MedTech (Group) Co EBITDA Margin % vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) has a EBITDA Margin % of 48.59% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai MicroPort Endovascular MedTech (Group) Co and its competitors. This is near median its historical median of 50.82. Over the past decade, Shanghai MicroPort Endovascular MedTech (Group) Co's EBITDA Margin % has ranged from 40.82 to 58.35. According to the industry distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #16 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 2%.
Is Shanghai MicroPort Endovascular MedTech (Group) Co's EBITDA Margin % too high?
Shanghai MicroPort Endovascular MedTech (Group) Co's current EBITDA Margin % of 48.59% is near median its 10-year median of 50.82. Over the past 10 years, this metric has ranged from a low of 40.82 to a high of 58.35. The Medical Devices & Instruments industry median EBITDA Margin % is 7.59. Shanghai MicroPort Endovascular MedTech (Group) Co's value of 48.59% is 540.2% above this industry median. Based on the distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #16 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai MicroPort Endovascular MedTech (Group) Co has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai MicroPort Endovascular MedTech (Group) Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #16 out of 816 companies for EBITDA Margin %. This places Shanghai MicroPort Endovascular MedTech (Group) Co in the top 2% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.59. Shanghai MicroPort Endovascular MedTech (Group) Co's value of 48.59% is 540.2% above this benchmark. Historically, Shanghai MicroPort Endovascular MedTech (Group) Co's own EBITDA Margin % has ranged from 40.82 to 58.35 over the past decade. While the company's 10-year median is 50.82 vs. the industry median of 7.59, Shanghai MicroPort Endovascular MedTech (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.59, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai MicroPort Endovascular MedTech (Group) Co's current EBITDA Margin % of 48.59% is 540.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai MicroPort Endovascular MedTech (Group) Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai MicroPort Endovascular MedTech (Group) Co's current EBITDA Margin % is 48.59%, which is near median its own 10-year median of 50.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai MicroPort Endovascular MedTech (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥112.35, compared to a current price of ¥95.13 — trading 15.3% below its estimated fair value. The current EBITDA Margin % is 48.59%, which is near median its 10-year median of 50.82 and 540.2% above the Medical Devices & Instruments industry median of 7.59. Shanghai MicroPort Endovascular MedTech (Group) Co's overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016), the current EBITDA Margin % is 48.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai MicroPort Endovascular MedTech (Group) Co stock appears to be undervalued.
The current stock price of ¥95.13 is trading 15.3% below its estimated GF Value™ of ¥112.35.
GuruFocus considers Shanghai MicroPort Endovascular MedTech (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:688016:
EBITDA Margin %: 48.59% (near median its 10-year median of 50.82)
GF Value™: ¥112.35 vs. price of ¥95.13 (15.3% below fair value)
Industry Position: 540.2% above the Medical Devices & Instruments median (#16 of 816)
No single metric tells the full story. See the SHSE:688016 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Microport Endovascular Medtech Co Ltd is engaged in the Research, development, production and sales of interventional medical devices for the aorta and peripheral blood vessels.
97GF Score
Get the complete analysis for SHSE:688016
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688016 has been successfully added to your 
